AstraZeneca therapy improves breast cancer survival in key trial
Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...
AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial
The drug candidate improved progression-free survival in patients, it said.
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
AstraZeneca therapy improves survival in late-stage breast cancer trial
Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in ...
GlobalData on MSN4d
AstraZeneca reports positive outcomes from breast cancer combo therapy trial
AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...
Daily22h
AstraZeneca-Daiichi Sankyo Enhertu recommended for approval in EU for patients with HER2-low or HER2-ultralow metastatic breast cancer
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...
FiercePharma9h
AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
FierceBiotech5d
AstraZeneca, eyeing $5B peak sales, reports phase 3 breast cancer win for oral SERD
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...
Pharm Exec4d
AstraZeneca’s Camizestrant Shows Survival Improvement for HR-Positive, HER2-Negative Advanced Breast Cancer with Emergent ESR1 Mutations
The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...
AstraZeneca breast cancer drug shows positive results, shares up
Bank of America analysts estimate a peak sales potential of $6 billion for camizestrant across the SERENA-6 and SERENA-4 ...
BioSpace5d
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...
Wall Street Journal5d
AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial
AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...